MAP2K7 and melanoma: During our investigation of the combinatorial antitumor effects of BRAF, MEK, and CDK4/6 inhibition in BRAFV600E-mutant PDTX melanoma models, results from a phase Ib/II clinical trial evaluating the same drug class combination in treatment naïve BRAFV600--mutant solid tumors, including melanoma, were recently presented at the 2017 American Society of Clinical Oncology (ASCO) meeting [44].